Brought to you by 
David Sarnoff & SmithKline create Orchid for drug screening
13 Jul 1999
Executive Summary
The David Sarnoff Research Center and SmithKline Beecham will collaborate to develop a device for the rapid synthesis and screening of molecules for drug discovery. Sarnoff will spin-off Orchid Biocomputer Inc. to carry out the agreement.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
David Sarnoff & SmithKline create Orchid for drug screening
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice